BibTeX
CSL-JSON
MLA
Harvard
Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
release_427nmst6onc2lnajgiivtfap2a
by
Walid Shalata,
Binil Mathew Jacob,
Abed Agbarya
Abstract
Lung cancer is the most common malignancy across the world. The new era in lung cancer treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both of which have led to improved survival rates. In the present study, we review the changes and development of treatments, with a special focus on adjuvant therapy using tyrosine kinase inhibitors (TKIs) administered to non-small-cell lung carcinoma patients who had a complete resection of the tumor harboring a mutated epidermal growth factor receptor. The clinical trials are dating from the past (chemotherapy trials), present (TKIs), and future (ongoing trials).
In application/xml+jats format
Archived Files and Locations
application/pdf
291.3 kB
file_pelts6r4jbamrljkrzsbyorx7u
|
res.mdpi.com (publisher) web.archive.org (webarchive) |
Web Captures
| https://www.mdpi.com/2072-6694/13/16/4119/htm
2022-07-01 04:23:42 | 35 resources webcapture_mubtcecu5vbsjed7igej3s3equ
|
web.archive.org (webarchive) |
Read Archived PDF
Preserved and Accessible
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:
2072-6694
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
access all versions, variants, and formats of this works (eg, pre-prints)
Cite This
Lookup Links
oaDOI/unpaywall (OA fulltext)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar